Application of ShSPI in preparation of medicine for treating or preventing thrombosis diseases

By using Hainan thorn centipede polypeptide ShSPI as an elastase inhibitor, platelet activation is inhibited, and the gastrointestinal irritation and drug resistance of existing antithrombotic drugs is solved, effective treatment and prevention of thrombotic diseases is achieved, and low toxicity is achieved. Side effects and high biosafety.

CN118903379APending Publication Date: 2024-11-08INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410986589.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-23
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing antithrombotic drugs have problems with gastrointestinal irritation and drug resistance when treating thrombotic diseases, and are not effective enough to inhibit platelet activation, making it difficult to meet clinical needs.

Method used

The polypeptide ShSPI from Hainan thorn centipede was used as an elastase inhibitor, which exerted anticoagulant effects by inhibiting platelet activation. It is used to prepare drugs for the treatment or prevention of thrombotic diseases. The effective dose is at least 0.4 mg/kg, and the form is intravenous infusion. preparation.

Benefits of technology

ShSPI can effectively inhibit thrombosis and platelet activation, have low toxic side effects and high biosafety. As a new safe antithrombotic drug, it can be used to treat or prevent thrombotic diseases, including ischemic stroke, and does not directly affect the coagulation pathway. , reduce the risk of bleeding.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903379A_ABST
    Figure CN118903379A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of novel pharmaceutical application of functional peptides, and particularly relates to application of ShSPI in preparation of drugs for treating or preventing thrombosis diseases. The centipede-derived polypeptide ShSPI disclosed by the invention is free from any toxic and side effects and high in biological safety; experiments prove that ShSPI has the effects of resisting thrombus, resisting platelets and treating cerebral arterial thrombosis, is low in action concentration and high in activity, and can be used for preparing medicines for treating or preventing thrombus diseases and medicines related to anticoagulation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of new pharmaceutical applications of functional peptides, and particularly relates to the application of ShSPI in the preparation of drugs for treating or preventing thrombotic diseases. Background Art

[0002] Elastase belongs to the chymotrypsin family of serine proteases. Elastase is a serine protease with a wide range of substrates that can degrade collagen, elastin, fibronectin and extracellular matrix proteins. Among them, ShSPI is an elastase inhibitor identified from the Hainan centipede, which can inhibit PPE (porcine pancreatic elastase) and HNE (human leukocyte elastase). Its protein sequence, three-dimensional structure, and elastase inhibition effect have been published, but ShSPI has not been reported in the development of thrombotic drugs and the therapeutic effect of ischemic stroke. Studies have shown that ShSPI has plasma stability, that is, 48 ​​hours in plasma does not affect its inhibitory effect on elastase, so it has a strong prospect for drug development and application.

[0003] Thrombosis is a type of disease that threatens human health and life. Cardiovascular and cerebrovascular diseases caused by thrombosis greatly affect the quality of human life. Ischemic stroke is caused by tissue damage due to blockage of blood vessels in the brain. It has the characteristics of high mortality and disability rates. Methods for restoring vascular patency include artificial mechanical methods, specifically balloon catheterization and surgical embolectomy, which bring huge physical and psychological burdens to patients. Antithrombotic therapy also includes the use of thrombolytic drugs, antiplatelet drugs and anticoagulants. Thrombolytic drugs can remove a formed thrombus, have the characteristics of less damage to the body, and are more easily accepted by patients. Common antithrombotic drugs are mainly divided into two categories: the first category is antiplatelet drugs, representative drugs are aspirin, clopidogrel, and ticagrelor. Anticoagulant drugs are the second category, representative drugs are warfarin, dabigatran, and rivaroxaban, these drugs are collectively referred to as antithrombotic drugs. These drugs have the characteristics of fast thrombolysis, but they are more irritating to the gastrointestinal tract, and are prone to drug resistance after taking them for 2 to 4 weeks.

[0004] Based on this, it is of great significance to explore a new anti-thrombotic drug. Summary of the invention

[0005] In order to overcome the problems of the prior art, the present invention proposes the use of ShSPI in the preparation of drugs for treating or preventing thrombotic diseases. ShSPI has the effects of anti-thrombosis, anti-platelet, and treatment of ischemic stroke, and has a low concentration and strong activity, and can be used to prepare drugs for treating or preventing thrombotic diseases, as well as anticoagulant-related drugs.

[0006] The object of the present invention is achieved in that:

[0007] The first aspect of the present invention provides the use of an elastase inhibitor in the preparation of a drug for treating or preventing thrombotic diseases, wherein the thrombotic diseases include thrombosis and ischemic stroke.

[0008] Furthermore, the elastase inhibitor is a centipede-derived polypeptide ShSPI, and its amino acid sequence is: CPQVCPAIYQPVFDEFGRMYSNSCEMQRARCLRG.

[0009] Furthermore, the anticoagulant effect is exerted by inhibiting platelet activation, thereby treating or preventing thrombotic diseases.

[0010] Furthermore, the effective dose of the polypeptide ShSPI in the drug is at least 0.4 mg / kg.

[0011] Furthermore, the drug is an intravenous infusion preparation.

[0012] A second aspect of the present invention provides an anticoagulant drug, which comprises centipede-derived polypeptide ShSPI and excipients.

[0013] The third aspect of the present invention provides a drug for preventing or treating thrombotic diseases, the drug comprising centipede-derived polypeptide ShSPI and excipients.

[0014] The present invention has no special restrictions on the types of the auxiliary materials, and any auxiliary materials known in the art can be used. The present invention has no special restrictions on the preparation method of the drug, and any preparation method of protein or polypeptide drugs known in the art can be used.

[0015] The advantages and beneficial effects of the present invention are:

[0016] 1. The present invention provides for the first time the use of ShSPI in the preparation of drugs for treating or preventing thrombotic diseases, opening up a new use of the centipede-derived polypeptide ShSPI.

[0017] 2. The present invention discovered that the centipede-derived polypeptide ShSPI can inhibit platelet activation, but at the same time does not completely block the coagulation cascade reaction and platelet activation. Therefore, compared with traditional coagulation factor inhibitors and antiplatelet drugs, elastase inhibitors have a lower risk of bleeding and are potential molecules for the development of new safe antithrombotic drugs. They can be used as new targets for the development of antithrombotic drugs.

[0018] 3. The centipede-derived polypeptide ShSPI described in the present invention has no toxic side effects and has high biological safety. Experiments have confirmed that ShSPI has anti-thrombotic, anti-platelet and ischemic stroke therapeutic effects, and has a low effective concentration and strong activity. It can be used to prepare drugs for treating or preventing thrombotic diseases, as well as anticoagulant-related drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] The present invention will be further described below in conjunction with the accompanying drawings and embodiments.

[0020] Figure 1 The figure shows the inhibitory effect of ShSPI on rat tail thrombosis in the rat tail thrombosis model induced by carrageenan; wherein A is the length of thrombus formed in the rat tail of each group of mice; B is the ratio of the length of thrombus formed in each mouse to the length of the mouse tail;

[0021] Figure 2 The activation of platelets in mice after ShSPI administration is shown; wherein A is a representative example of the activation degree of platelets isolated from mice after ADP activation over time, and B is a statistical chart of the maximum activation degree of platelets isolated from each group of mice after ADP activation;

[0022] Figure 3 The effect of polypeptide ShSPI on the coagulation pathway is shown, wherein A is the comparison result of recalcification time; B is the comparison result of activated partial thromboplastin time (APTT); C is the comparison result of prothrombin time (PT);

[0023] Figure 4 The figure shows the inhibitory effect of ShSPI on stroke formation in the tMCAO model; wherein A is a staining diagram of the brain tissue of the model mice, and B, C, and D are the grasping ability test results, Zea Longa and Bederson neurobehavioral score statistics of each group of model mice, respectively;

[0024] Figure 5 The cytotoxicity and hemolytic activity of ShSPI are shown; A and B are the cytotoxicity results of ShSPI on RAW264.7 and EA.hy926 cells, respectively; and C is the hemolytic effect of ShSPI on erythrocytes. DETAILED DESCRIPTION

[0025] The examples are provided to better illustrate the present invention, but the present invention is not limited to the examples. Therefore, those skilled in the art may make non-essential improvements and adjustments to the implementation scheme according to the above invention content, which still fall within the protection scope of the present invention.

[0026] The endpoints and any values ​​of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of each range, the endpoint values ​​of each range and the individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.

[0027] The present invention will be described in detail below by way of examples. It should be understood that the following examples are only used to further explain and illustrate the content of the present invention in detail, and are not used to limit the present invention.

[0028] In the following examples, the preparation method of centipede-derived polypeptide ShSPI is described in: ZL 201810571432.

[0029] Example 1: Antithrombotic effect of ShSPI

[0030] In this example, a rat tail thrombosis model induced by carrageenan was constructed to detect the anti-thrombotic effect of ShSPI polypeptide. The specific model construction and operation process are as follows:

[0031] ICR mice (23-26 g) were used in the experiment and divided into 6 groups.

[0032] Mice in the normal group were injected with 100 μL of normal saline via the tail vein, and half an hour later, 100 μL of normal saline was injected intraperitoneally.

[0033] Mice in the peptide control group were injected with 100 μL ShSPI at a concentration of 2 mg / kg via the tail vein, and injected with 100 μL normal saline intraperitoneally half an hour later.

[0034] Mice in the model group were injected with 100 μL of normal saline via the tail vein, and 100 μL of carrageenan was injected intraperitoneally half an hour later.

[0035] Mice in the low-concentration, medium-concentration, and high-concentration peptide treatment groups were injected with 100 μL ShSPI via the tail vein at concentrations of 0.5, 1, and 2 mg / kg, respectively, and injected intraperitoneally with 100 μL carrageenan half an hour later.

[0036] The injected carrageenan was prepared with physiological saline to a concentration of 0.2%. When injected into the mouse peritoneum, the mouse was weighed and injected at a dose of 10 g mouse / 100 μL. All mice were placed in a low temperature treatment of 16°C, and the thrombosis of the mouse tail was observed after 24 hours, and the total length of the mouse tail and the length of the black tail were measured.

[0037] The results are as follows Figure 1 As shown, A is the length of thrombus formed in the tail of each group of mice. Treatment with ShSPI at a concentration of 0.5, 1, and 2 mg / kg can reduce the average tail thrombus length of 7.4 cm formed in the carrageenan group to about 6.95, 6.55, and 5 cm, respectively; B is the ratio of the length of thrombus formed in each mouse to the length of the mouse tail. Treatment with ShSPI at a concentration of 0.5, 1, and 2 mg / kg can reduce the thrombus ratio of 85.8% formed in the carrageenan group to about 81.5%, 76%, and 56%, respectively.

[0038] The results showed that ShSPI inhibited the formation of rat tail thrombus at concentrations of 1 mg / kg and 2 mg / kg, indicating that ShSPI has an anti-thrombotic effect in vivo.

[0039] Example 2: Antiplatelet effect of ShSPI

[0040] This example detects the anti-platelet effect of ShSPI polypeptide, and the specific method is as follows:

[0041] C57BL / 6 mice (20-22 g) were randomly divided into 4 groups and injected with saline, 0.25, 1 and 4 mg / kg ShSPI via the tail vein, with an injection volume of 100 μL per mouse. Two hours later, whole blood from the mice was collected into anticoagulation tubes, which were centrifuged at 400 g for 5 minutes in a centrifuge, and the upper plasma layer was collected into a new tube. The tubes were washed twice with benchtop solution, and the precipitate was collected after centrifugation for 5 minutes, which was the unactivated platelets. The unactivated platelets were resuspended, 20 μM ADP was added, and platelet activation data were collected using a platelet activation instrument for 5 minutes.

[0042] The results are as follows Figure 2 As shown, the extent of platelet activation by ADP in mice pre-injected with 0.25, 1 and 4 mg / kg ShSPI was significantly inhibited, indicating that ShSPI inhibited platelet activation in mice.

[0043] Example 3: ShSPI does not directly affect the coagulation system

[0044] In order to explore the effect of ShSPI polypeptide on the coagulation system in vivo, the following tests were performed in this example:

[0045] The APTT / PT reagent was balanced to room temperature and gently inverted to mix. CaCl2 was preheated in a 37°C incubator for later use. The steps for the recalcification activity test were as follows: Prepare Hepes buffer (10mM Hepes, 150mM NaCl, adjust pH to 7.5 with NaOH), add 50μL of APTT reagent, 20μL of plasma, 10μL of peptide, and 70μL of Hepes buffer to a 96-well plate, incubate at 37°C for 10 minutes, add 50μL of CaCl2 solution, and then detect the absorbance change at 650nm on an enzyme-labeled instrument. The steps for detecting APTT activity were as follows: Add 50μL of APTT reagent, 40μL of plasma, and 10μL of peptide to a 96-well plate, incubate at 37°C for 3 minutes, add 50μL of CaCl2 solution, and then detect the absorbance change at 650nm on an enzyme-labeled instrument. The steps for detecting PT activity are as follows: 40 μL of plasma and 10 μL of polypeptide were added to a 96-well plate in sequence, and after incubation at 37°C for 3 minutes, 50 μL of PT reagent was added, and then the absorbance change at 650 nm was detected on an enzyme reader.

[0046] The results are as follows Figure 3 As shown, ShSPI has no significant effect on recalcification, APTT, and PT time at a concentration of 50 μg / mL, indicating that the peptide ShSPI does not directly affect the coagulation pathway, and has a low risk of bleeding when developed as a drug.

[0047] Example 4: Therapeutic effect of ShSPI on ischemic stroke

[0048] In this example, the tMCAO suture embolization method was used to induce a stroke model in mice to detect the therapeutic effect of ShSPI polypeptide on ischemic stroke. The specific model construction and operation process are as follows:

[0049] C57BL / 6 mice (20-22 g) were randomly divided into 4 groups. The mice were anesthetized with 2% sodium pentobarbital (80 mg / kg). The skin and subcutaneous tissue of the mice were cut layer by layer through the midline incision of the mouse neck to expose the right common carotid artery, internal carotid artery and external carotid artery. The thyroid artery and pharyngeal artery on the external carotid artery were coagulated and cut using an electrocoagulator. The distal end of the external carotid artery was ligated, and the line was hung on its proximal end to temporarily clamp the right common carotid artery and internal carotid artery. The external carotid artery was cut, and the line plug was inserted from the stump of the external carotid artery into the internal carotid artery. The stump of the external carotid artery was ligated, and the artery clamp of the internal carotid artery was removed. The line plug was slowly pushed inward and upward from the internal carotid artery. The direction was adjusted appropriately, and the line plug was inserted to the line plug mark (10 mm from the bifurcation of the right common carotid artery). The timing was started, and the line plug was removed and the incision was sutured after 1 hour. Each group of mice was injected with drugs, and the sham operation group and the model group were injected with normal saline through the tail vein, and the polypeptide group was injected with 0.25mg / kg and 1mg / kg of ShSPI. After the mice woke up, they were put back in the cage and allowed to eat freely. After 24 hours, the mice were taken out for muscle strength test, Bederson neurological function score, balance beam walking test, etc., and neurobehavioral score was completed. Then the mice were anesthetized, the mouse brain tissue was taken out, placed in a pre-cooled brain mold, cut into 2mm thick slices with a clean blade, and the slices were placed in phosphate buffer containing 2% TTC and placed in a 37℃ incubator for staining for 30min. Then the slices were moved to 4% paraformaldehyde for fixation, photography, and statistical data.

[0050] The results are as follows Figure 4 As shown, ShSPI at concentrations of 0.25 mg / kg and 1 mg / kg showed the effect of inhibiting the formation of cerebral thrombus and treating stroke. At the above concentrations, ShSPI can inhibit the cerebral thrombosis induced by the model to a level close to that of normal mice.

[0051] Example 5: Detection of toxic and side effects of ShSPI

[0052] In order to evaluate whether the ShSPI polypeptide has toxic side effects on the body, the following tests were performed in this example:

[0053] Thp-1 and EA.hy926 cells were cultured in a cell culture medium containing 10% fetal bovine serum and 1% double antibody at 37°C and 5% CO2. The cells were seeded in a 96-well plate at a seeding concentration of 4×10 5 / mL culture medium, 100μL was inoculated into each well. Overnight culture allowed the cells to adhere to the wall. After the cells adhered to the wall, the cells were washed twice with PBS and then cultured with serum-free cell culture medium. After overnight, the cells were treated with different concentrations of ShSPI polypeptide, which were 1000, 500, 250, 125, 62.5, 31.25, 15.63, 7.81, 3.91, and 0μg / mL. After 18 hours of culture, the culture supernatant was discarded, 100μL of CCK-8 reagent was added to each well, and the absorbance at 450nm was detected in an ELISA reader after 2 hours, and the statistics were calculated.

[0054] Fresh blood from mice was collected in EDTA anticoagulant tubes, centrifuged at 1000g for 5 min at room temperature, the supernatant was discarded, and red blood cells were collected. The red blood cells were washed with saline for 3 times until the supernatant no longer appeared red, and then the red blood cells were resuspended in saline. 100 μL of ShSPI polypeptide solution of different concentrations and 100 μL of red blood cell suspension were added to each well of a 96-well plate. The final concentrations of ShSPI were 1500, 750, 375, 187.5, 93.75, 46.88, 23.44, 11.72, 5.86, 2.93, 1.46, and 0.73 μg / mL, respectively. 1% Triton X-100 solution was used as a positive control and placed in a 37°C incubator for 1 hour. The absorbance value at 540 nm was measured by an enzyme marker. Sterile saline and 1% Triton X-100 represent 0% and 100%, respectively.

[0055] The hemolysis rate of polypeptides at different concentrations was calculated according to the formula: hemolysis rate (%) = (absorbance of experimental group - absorbance of negative control group) / (absorbance of positive control group - absorbance of negative control group) × 100%, and the results were statistically analyzed and plotted.

[0056] The results are as follows Figure 5 As shown, ShSPI has no obvious cytotoxicity to cells at a concentration of up to 1000 μg / mL, and only has about 7% hemolytic toxicity at a concentration of 1500 μg / mL. The above data prove that ShSPI has no toxic side effects at normal use concentrations (less than 1000 μg / mL) and has high biological safety.

[0057] In summary, the Hainan centipede-derived polypeptide ShSPI provided by the present invention is a specific inhibitor of elastase, which can inhibit 95% of the activity of porcine pancreas-derived elastase and 97% of the activity of human leukocyte-derived elastase at a concentration of 10 μg / mL. Experiments were conducted on a thrombotic mouse model, and it was found that ShSPI can effectively prevent and treat the formation of thrombi. It can be seen that the elastase inhibitor polypeptide ShSPI provided by the present invention has the effects of anti-thrombosis, anti-platelet, and treatment of ischemic stroke, and has a low concentration and strong activity, and can be used to prepare anti-thrombotic drugs.

[0058] Finally, it should be noted that the above is only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred arrangement scheme, a person skilled in the art should understand that the technical solution of the present invention may be modified or replaced by equivalents without departing from the spirit and scope of the technical solution of the present invention.

Claims

1. Use of an elastase inhibitor in the preparation of a drug for treating or preventing thrombotic diseases, characterized in that: The thrombotic diseases include thrombosis and ischemic stroke.

2. The use according to claim 1, characterized in that: The elastase inhibitor is a centipede-derived polypeptide ShSPI, and its amino acid sequence is: CPQVCPAIYQPVFDEFGRMYSNSCEMQRARCLRG.

3. The use according to claim 1, characterized in that: It exerts an anticoagulant effect by inhibiting platelet activation, thereby treating or preventing thrombotic diseases.

4. The use according to claim 2, characterized in that: The effective dose of the polypeptide ShSPI in the medicine is at least 0.4 mg / kg.

5. The use according to any one of claims 1 to 4, characterized in that: The medicine is an intravenous infusion preparation.

6. An anticoagulant drug, characterized in that: The drug comprises centipede-derived polypeptide ShSPI and excipients, and the amino acid sequence of the polypeptide ShSPI is: CPQVCPAIYQPVFDEFGRMYSNSCEMQRARCLRG.

7. A drug for preventing or treating thrombotic diseases, characterized in that: The drug comprises centipede-derived polypeptide ShSPI and excipients, and the amino acid sequence of the polypeptide ShSPI is shown in SEQ ID NO:

1.

8. The drug according to claim 7, characterized in that The thrombotic diseases include thrombosis and ischemic stroke.

9. The drug according to any one of claims 6 to 8, characterized in that The effective dose of the polypeptide ShSPI in the medicine is at least 0.4 mg / kg.

10. The drug according to any one of claims 6 to 8, characterized in that The medicine is an intravenous infusion preparation.

Citation Information

Patent Citations

  • Application of antibacterial peptide BF-30 in preparation of medicines for treating or preventing thrombotic diseases

    CN105012936A

  • Elastic protease inhibitor LNSP-I and application thereof

    CN108840927A

  • Application of polypeptide PD-DP-005 in preparation of medicine for treating lung diseases and medicine of polypeptide PD-DP-005

    CN116421704A